A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

NCT07069712 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroesophageal Adenocarcinoma

Interventions

DRUG: AZD0901
DRUG: Rilvegostomig
DRUG: Trastuzumab Deruxtecan (T-DXd)
DRUG: Capecitabine
DRUG: 5-Fluorouracil (5-FU)
DRUG: FLOT Chemotherapy

Sponsor

AstraZeneca

Collaborators

[object Object]